. Author manuscript; available in PMC: 2024 Mar 1.

Published in final edited form as: Science. 2022 May 26;376(6596):991–996. doi: 10.1126/science.abn4213

Table 1.

Activity of cilagicin against microorganisms and human cells.

Pathogens/Human cells	Cilagicin MIC (μg/mL)^a

Gram-positive
Staphylococcus aureus USA300 (MRSA)	1
Staphylococcus aureus BAA1717(BRSA)	0.5
Enterococcus faecium EF18 (VRE)	0.5
Enterococcus faecalis AR785 (VRE)	0.5
Enterococcus gallinarum AR784 (VRE)	0.5
Enterococcus casseliflavus AR798 (VRE)	0.125
Streptococcus pneumoniae R^b	0.5
Streptococcus pneumoniae Tigr4^b	0.25
Clostridium difficile HM89^c	2
Clostridium difficile HM746^c	2
Streptococcus pyrogens ATCC19615	0.125
Streptococcus agalactiae BAA2675	1
Streptococcus agalactiae BAA1176	1
Bacillus subtilis 168A1	2
Gram-negative
Acinetobacter baumannii ATCC17978	8
Escherichia coli BAS849	4
Escherichia coli ATCC25922	>64
Klebsiella pneumoniae ATCC13833	>64
Pseudomonas aeruginosa PAO1	>64
Enterobacter cloacae ATCC13047	>64
Human cell line
HEK293	>64^c

The MIC was tested by broth microdilution.

Bacteria were cultured under 5% CO2;

Bacteria were cultured under anaerobic condition; MRSA, methicillin-resistant S. aureus; BRSA, bacitracin-resistant S. aureus; VRE, vancomycin-resistant Enterococci.

IC50